⌕
Jazz Pharmaceuticals · JAZZ · Nasdaq
Tenet 47 · Mixed
Compare
$240.71+0.39%At closeTenet 47 · Mixed
$240.71+0.94 (+0.39%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Jazz Pharmaceuticals (JAZZ) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~8.4%/yr (FY21→FY25), net margin −8.3%. Worth your attention in FY25: Capex step-up ($916.8M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲4.9%
4,267.6
FY21→FY25CAGR +8.4%/yr
Net income ($M)—
−356.1
one-off year: see footnoteCAGR —
Free cash flow ($M)▼67.7%
439.0
capex stepped upCAGR −12.6%/yr
Diluted EPS—
−5.84
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+2.2%

59.7mn → 61.0mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex step-up
$916.8M

▲2308% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
28%

$125.0M returned vs $439.0M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)4267.6Revenue−503.3COGS3764.3Gross profit−1730.6R&D−1809.3SG&A−430.2Op income74.1Tax & other−356.1Net income

-8¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY21FY25

Over this window: gross 85.8% → 88.2%. Net margin -8.3% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
4,718.24,267.64,068.93,834.23,659.43,094.2▲4.9%+8.4%
Cost of revenue
514.6503.3445.7435.6540.5440.8▲12.9%+3.4%
Gross profit
4,203.63,764.33,623.23,398.63,118.92,653.5▲3.9%+9.1%
Research & development
1,660.51,730.6894.0868.71,034.6505.7▲93.6%+36.0%
Selling, general & admin
1,556.11,809.31,385.31,343.11,417.01,451.7▲30.6%+5.7%
Total operating expenses
3,777.64,194.52,906.62,820.03,184.42,483.2▲44.3%+14.0%
Operating incomefeeds ROC rank
426.0−430.2716.6578.6−65.5170.3——
Other income, net
−166.1−197.6−246.3−280.7−307.3−283.1——
Pretax income
259.8−627.9470.4297.9−372.8−112.8——
Income tax
53.7−272.4−91.4−119.9−158.6216.1▼198.0%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
206.0−356.1560.1414.8−224.1−329.7——
Per share
Diluted EPSbuyback-sensitive
3.07−5.848.656.10−3.58−5.52——
Diluted shares (mn)
64.7060.9866.0172.0762.5459.69▼7.6%+0.5%
Margins
Gross margin84th pct in Healthcare
89.1%88.2%89.0%88.6%85.2%85.8%▼0.8pp+2.5pp
Operating margin
9.0%−10.1%17.6%15.1%−1.8%5.5%▼27.7pp−15.6pp
Net margin54th pct in Healthcare
4.4%−8.3%13.8%10.8%−6.1%−10.7%▼22.1pp+2.3pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −192% vs a −19% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 43% vs a −19% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Jazz Pharmaceuticals' revenue last fiscal year?

Jazz Pharmaceuticals reported revenue of $4,267.6M in fiscal 2025, up 4.9% from fiscal 2024.

What was Jazz Pharmaceuticals' net income?

Jazz Pharmaceuticals reported net income of −$356.1M in fiscal 2025, a net margin of −8.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.